Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CARs on track in the clinic.

Literature DB >> 21358705

CARs on track in the clinic.

Donald B Kohn¹, Gianpietro Dotti, Renier Brentjens, Barbara Savoldo, Michael Jensen, Laurence Jn Cooper, Carl H June, Steven Rosenberg, Michel Sadelain, Helen E Heslop.

Abstract

Mesh：

Substances：
Receptors, Antigen

Year: 2011 PMID： 21358705 PMCID： PMC3048197 DOI： 10.1038/mt.2011.1

Source DB: PubMed Journal: Mol Ther ISSN： 1525-0016 Impact factor: 11.454

× No keyword cloud information.

43 in total

1. Safer CARS.

Authors: Helen E Heslop
Journal: Mol Ther Date: 2010-04 Impact factor: 11.454

2. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors: John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal: Nat Biotechnol Date: 2002-01 Impact factor: 54.908

Review 3. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors: Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal: Blood Date: 2010-05-03 Impact factor: 22.113

4. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.

Authors: J B Latouche; M Sadelain
Journal: Nat Biotechnol Date: 2000-04 Impact factor: 54.908

5. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.

Authors: Kenneth P Micklethwaite; Barbara Savoldo; Patrick J Hanley; Ann M Leen; Gail J Demmler-Harrison; Laurence J N Cooper; Hao Liu; Adrian P Gee; Elizabeth J Shpall; Cliona M Rooney; Helen E Heslop; Malcolm K Brenner; Catherine M Bollard; Gianpietro Dotti
Journal: Blood Date: 2010-01-28 Impact factor: 22.113

Review 6. Building better chimeric antigen receptors for adoptive T cell therapy.

Authors: John S Bridgeman; Robert E Hawkins; Andreas A Hombach; Hinrich Abken; David E Gilham
Journal: Curr Gene Ther Date: 2010-04 Impact factor: 4.391

7. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.

Authors: R E Walker; C M Bechtel; V Natarajan; M Baseler; K M Hege; J A Metcalf; R Stevens; A Hazen; R M Blaese; C C Chen; S F Leitman; J Palensky; J Wittes; R T Davey; J Falloon; M A Polis; J A Kovacs; D F Broad; B L Levine; M R Roberts; H Masur; H C Lane
Journal: Blood Date: 2000-07-15 Impact factor: 22.113

8. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

Authors: Michael C Jensen; Leslie Popplewell; Laurence J Cooper; David DiGiusto; Michael Kalos; Julie R Ostberg; Stephen J Forman
Journal: Biol Blood Marrow Transplant Date: 2010-03-19 Impact factor: 5.742

9. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.

Authors: V Hoyos; B Savoldo; C Quintarelli; A Mahendravada; M Zhang; J Vera; H E Heslop; C M Rooney; M K Brenner; G Dotti
Journal: Leukemia Date: 2010-04-29 Impact factor: 11.528

Review 10. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".

Authors: Gianpietro Dotti; Barbara Savoldo; Malcolm Brenner
Journal: Hum Gene Ther Date: 2009-11 Impact factor: 5.695

60 in total

1. Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors: Sergio Rutella; Franco Locatelli
Journal: Am J Transl Res Date: 2011-09-10 Impact factor: 4.060

2. A new cellular weapon to kill leukaemic B-cells.

Authors: Mohamed-Rachid Boulassel
Journal: Sultan Qaboos Univ Med J Date: 2012-04-09

3. Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors: Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal: Hum Gene Ther Date: 2012-04-18 Impact factor: 5.695

4. Engineered T-cell therapy shows efficacy in blood cancer.

Authors: Simon Frantz
Journal: Nat Biotechnol Date: 2011-10-13 Impact factor: 54.908

5. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors: David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245

6. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors: Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal: Sci Transl Med Date: 2011-08-10 Impact factor: 17.956

7. SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

Authors: Siwen Hu-Lieskovan; Srabani Bhaumik; Kavita Dhodapkar; Jean-Charles J B Grivel; Sumati Gupta; Brent A Hanks; Sylvia Janetzki; Thomas O Kleen; Yoshinobu Koguchi; Amanda W Lund; Cristina Maccalli; Yolanda D Mahnke; Ruslan D Novosiadly; Senthamil R Selvan; Tasha Sims; Yingdong Zhao; Holden T Maecker
Journal: J Immunother Cancer Date: 2020-12 Impact factor: 13.751